(phosphodiesterase 5 inhibitors & α-blockers): single versus combined therapy in benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: to compare between efficacy of phosphodiesterase5 inhibitors (tadalafil 5 mg) and alpha blockers (tamsulosin 0.4 mg) monotherapy vs combined therapy in treatment of lower urinary tract symptoms of benign prostatic hyperplasia.

the proposed research aims to answer the question about efficacy and safety of phosphodiesterase 5 inhibitors (tadalafil 5 mg) and alpha blockers (tamsulosin 0.4 mg) monotherapy vs combined therapy in treatment of lower urinary tract symptoms of benign prostatic hyperplasia . benign prostatic hyperplasia (bph) is a disorder histologically characterized as the non-malignant hyperplasia of prostatic cells. most of patients with bph present with lower urinary tract symptoms (luts). about half of men develop bph, among those; about half develop some degree of bladder outlet obstruction (boo). boo and/or changes in smooth muscle tone and resistance that can accompany bph may result in (luts). alpha-blockers have been widely used for the treatment of luts/bph for a long time. some alpha-blockers may cause ejaculatory dysfunction in some individuals. tadalafil, a (pde-5), was approved by the food and drug administration (fda) for the treatment of (ed) in 2003 and for the treatment of bph in 2011. the pde5 inhibitors are used in the treatment of ed and there are increasing data of effects of these drugs on bladder and urethral relaxation as well as of prostatic smooth muscles that may relief the symptoms of bph. medical treatments for luts/bph are able to significantly impact on sexual function. sexual side effects like ejaculatory dysfunction, reduced or lost libido, and ed have been widely reported in patients treated with alpha blockers (abs) and 5-alpha reductase inhibitors, the most utilized drugs for the treatment of luts/bph. the inclusion of tadalafil in complex of combined conservative therapy of patients with bph not only improves sexual function but has a positive effect on symptoms of the disease and the psychological state of the patient.

Eligibility criteria:
inclusion criteria: 1 - men \> 45 years with luts/bph for \> 6 months 2- ipss of ≥ 8 and qmax of ≥ 4 to≤ 15 ml/s exclusion criteria: 1. psa level of \> 10.0 ng/ml (if ≥ 4.0 to≤ 10.0 ng/ml prostate cancer will be excluded). 2. post-voidresidual urine volume of ≥ 150 ml. 3. previous urine retention or urethral catheterization . 4. other pathology such as urinary bladder stone , bladder mass or neurogenic bladder . 5. any case of luts other than bph (urinary bladder stone, neurogenic bladder, bladder neck contracture,rethral stricture, bladder cancer, acute or chronic prostatitis, acute or chronic urinary tract infection). 6. patients supposed to undergo intraocular operation (as cataract operation) . 7. history of head injury or cerebrovascular stroke or spinal injury. 8. pelvic fracture. 9. uncontrolled diabetic patient. 10. patients with chronic obstructive lung disease on medical treatment. 11. parasympatholytic drugs are contraindicated during the study. 12. patients refusing to share in the study.

Keywords: phosphodiesterase5 inhibitors and alpha blockers